TGFBR1*6A is a potential modifier of migration and invasion in colorectal cancer cells

Zhou,Rui; Huang,Ying; Cheng,Boran; Wang,Yulei; Xiong,Bin

doi:10.3892/ol.2018.7725

TGFBR1*6A is a potential modifier of migration and invasion in colorectal cancer cells

Authors:
- Rui Zhou
- Ying Huang
- Boran Cheng
- Yulei Wang
- Bin Xiong
View Affiliations

Affiliations: Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Gastrointestinal Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China
Published online on: January 4, 2018 https://doi.org/10.3892/ol.2018.7725
Pages: 3971-3976

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Type 1 transforming growth factor β receptor (TGFBR1)*6A, a common hypomorphic variant of TGFBR1, may act as a susceptibility allele in colorectal cancer. However, the contribution of TGFBR1*6A to colorectal cancer development is largely unknown. To test the hypothesis that TGFBR1*6A promotes colorectal cancer invasion and metastasis via Smad‑independent transforming growth factor‑β (TGF‑β) signaling, the effect of TGFBR1*6A on the invasion of colorectal cancer cells was assessed. pCMV5‑TGFBR1*6A‑HA plasmids were transfected into SW48 and DLD‑1 cells by Lipofectamine-mediated DNA transfection. The effect of TGF‑β1 on the proliferation of SW48 and DLD‑1 cells transfected with TGFBR1*6A was determined by MTT assay. The effects of the TGF‑β1 on the invasion of the transfected SW48 and DLD‑1 cells were determined using Matrigel‑coated plates. Transforming migrating chambers were used to determine the effects of TGF‑β1 on the migration of the transfected SW48 and DLD‑1 cells. Western blot analysis was used to determine the expression of phosphorylated (p‑) extracellular‑signal‑regulated kinase (ERK), p‑P38 and p‑SMAD family member 2 in SW48 cells. Using transfected TGFBR1*6A SW48 and DLD‑1 cell lines our group demonstrated that, in comparison with TGFBR1*9A, TGFBR1*6A is capable of switching TGF‑β1 growth‑inhibitory signals into growth‑stimulatory signals which significantly increased the invasion of SW48 and DLD‑1 cells. Functional assays indicated that TGFBR1*6A weakened Smad‑signaling but increased ERK and p38 signaling, which are crucial mediators of cell migration and invasion. From this, it was possible to conclude that TGFBR1*6A enhanced SW48 cell migration and invasion through the mitogen‑activated protein kinase pathway and that it may contribute to colorectal cancer progression in a TGF‑β1/Smad signaling‑independent manner. This suggests that TGFBR1*6A may possess oncogenic properties and that it may affect the migration and invasion of colorectal cancer cells.

View Figures

View References

1	David CJ, Huang YH, Chen M, Su J, Zou Y, Bardeesy N, Iacobuzio-Donahue CA and Massagué J: TGF-β tumor suppression through a lethal EMT. Cell. 164:1015–1030. 2016. View Article : Google Scholar : PubMed/NCBI
2	Principe DR, Doll JA, Bauer J, Jung B, Munshi HG, Bartholin L, Pasche B, Lee C and Grippo PJ: TGF-β: Duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst. 106:djt3692014. View Article : Google Scholar : PubMed/NCBI
3	Mehrvarz Sarshekeh A, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E, Manuel S, et al: Association of SMAD4 mutation with patient demographics, tumor characteristics and clinical outcomes in colorectal cancer. PLoS One. 12:e01733452017. View Article : Google Scholar : PubMed/NCBI
4	Ramamoorthi G and Sivalingam N: Molecular mechanism of TGF-β signaling pathway in colon carcinogenesis and status of curcumin as chemopreventive strategy. Tumour Biol. 35:7295–7305. 2014. View Article : Google Scholar : PubMed/NCBI
5	PLOS ONE Staff: Correction: Association of SMAD4 mutation with patient demographics, tumor characteristics and clinical outcomes in colorectal cancer. PLoS One. 12:e01782752017. View Article : Google Scholar : PubMed/NCBI
6	Fleming NI, Jorissen RN, Mouradov D, Christie M, Sakthianandeswaren A, Palmieri M, Day F, Li S, Tsui C, Lipton L, et al: SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Res. 73:725–735. 2013. View Article : Google Scholar : PubMed/NCBI
7	Sarshekeh AM, Overman MJ, Kee BK, Fogelman DR, Dasari A and Singh Raghav KP: Demographic, tumor characteristics and outcomes associated with SMAD4 mutation in colorectal cancer. J Clin Oncol. 34:5652016. View Article : Google Scholar
8	Sun XF, Sun XH, Cheng SF, Wang JJ, Feng YN, Zhao Y, Yin S, Hou ZM, Shen W and Zhang XF: Interaction of the transforming growth factor-β and Notch signaling pathways in the regulation of granulosa cell proliferation. Reprod Fertil Dev. 28:1873–1881. 2015. View Article : Google Scholar
9	Liu WT, Huang KY, Lu MC, Huang HL, Chen CY, Cheng YL, Yu HC, Liu SQ, Lai NS and Huang HB: TGF-β upregulates the translation of USP15 via the PI3K/AKT pathway to promote p53 stability. Oncogene. 36:2715–2723. 2017. View Article : Google Scholar : PubMed/NCBI
10	Jung B, Staudacher JJ and Beauchamp D: Transforming growth factor βsuper family signaling in development of colorectal cancer. Gastroenterology. 152:36–52. 2016. View Article : Google Scholar : PubMed/NCBI
11	Hu YS, Pan Y, Li WH, Zhang Y, Li J and Ma BA: Association between TGFBR1*6A and osteosarcoma: A Chinese case-control study. BMC Cancer. 10:1692010. View Article : Google Scholar : PubMed/NCBI
12	Wang Y, Qi X, Wang F, Jiang J and Guo QN: Association between TGFBR1 polymorphisms and cancer risk: A meta-analysis of 35 case-control studies. PLoS One. 7:e428992012. View Article : Google Scholar : PubMed/NCBI
13	Zhang X, Wu L, Sheng Y, Zhou W, Huang Z, Qu J, Gao G, Cai D and Zhang M: The association of polymorphisms on TGFBR1 and colorectal cancer risk: A meta-analysis. Mol Biol Rep. 39:2567–2574. 2012. View Article : Google Scholar : PubMed/NCBI
14	Rosman DS, Phukan S, Huang CC and Pasche B: TGFBR1*6A enhances the migration and invasion of MCF-7 breast cancer cells through rhoa activation. Cancer Res. 68:1319–1328. 2008. View Article : Google Scholar : PubMed/NCBI
15	Pasche B, Pennison MJ, Jimenez H and Wang M: TGFBR1 and cancer susceptibility. Trans Am Clin Climatol Assoc. 125:300–312. 2014.PubMed/NCBI
16	Castillejo A, Mata-Balaguer T, Montenegro P, Ochoa E, Lázaro R, Martínez-Cantó A, Castillejo MI, Guarinos C, Barberá VM, Guillén-Ponce C, et al: The TGFBR1*6A, allele is not associated with susceptibility to colorectal cancer in a Spanish population: A case-control study. BMC Cancer. 9:1932009. View Article : Google Scholar : PubMed/NCBI
17	Ross JP, Lockett LJ, Tabor B, Saunders IW, Young GP, Macrae F, Blanco I, Capella G, Brown GS, Lockett TJ and Hannan GN: Little evidence for association between the TGFBR1*6A variant and colorectal cancer: A family-based association study on non-syndromic family members from Australia and Spain. BMC Cancer. 14:4752014. View Article : Google Scholar : PubMed/NCBI
18	McGuire JL, Mcphail M and Rajendran A: The association of tgfβ signalling pathway gene polymorphisms with colorectal cancer risk: A meta-analysis. Gastroenterology. 146:S868–S8683. 2014. View Article : Google Scholar
19	Ibrahim T, Yazbeck C, Maalouly G, Haddad F, Sabbagh C and Chahine G: TGFBR1*6A polymorphism in sporadic and familial colorectal Carcinoma: A case-control study and systematic literature review. J Gastrointestinal Cancer. 45:441–447. 2014. View Article : Google Scholar
20	Pasche B, Kaklamani V, Hou N, Young T, Rademaker A, Peterlongo P, Ellis N, Offit K, Caldes T, Reiss M and Zheng T: TGFBR1*6A and cancer: A meta-analysis of 12 case-control studies. J Clin Oncol. 22:756–758. 2004. View Article : Google Scholar : PubMed/NCBI
21	Ross JP, Lockett LJ, Tabor B, Saunders IW, Young GP, Macrae F, Blanco I, Capella G, Brown GS, Lockett TJ and Hannan GN: Little evidence for association between the TGFBR1*6A variant and colorectal cancer: A family-based association study on non-syndromic family members from Australia and Spain. BMC Cancer. 14:4752014. View Article : Google Scholar : PubMed/NCBI
22	Pasche B, Luo Y, Rao PH, Nimer SD, Dmitrovsky E, Caron P, Luzzatto L, Offit K, Cordon-Cardo C and Renault B: Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract. Cancer Res. 58:2727–2732. 1998.PubMed/NCBI
23	Pasche B, Knobloch TJ, Bian Y, Liu J, Phukan S, Rosman D, Kaklamani V, Baddi L, Siddiqui FS, Frankel W, et al: Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA. 294:1634–1646. 2005. View Article : Google Scholar : PubMed/NCBI
24	Wu WK, Wang XJ, Cheng AS, Luo MX, Ng SS, To KF, Chan FK, Cho CH, Sung JJ and Yu J: Dysregulation and crosstalk of cellular signaling pathways in colon carcinogenesis. Crit Rev Oncol Hematol. 86:251–277. 2013. View Article : Google Scholar : PubMed/NCBI
25	Taves S, Berta T, Liu DL, Gan S, Chen G, Kim YH, Van de Ven T, Laufer S and Ji RR: Spinal inhibition of p38 MAP kinase reduces inflammatory and neuropathic pain in male but not female mice: Sex-dependent microglial signaling in the spinal cord. Brain Behav Immun. 55:70–81. 2016. View Article : Google Scholar : PubMed/NCBI